Epidemiologic Aspects of Fungal Infections (Tom M. Chiller, Section Editor)

Current Fungal Infection Reports

, 5:206

First online:

Preventing Death from HIV-Associated Cryptococcal Meningitis: The Way Forward

  • Monika RoyAffiliated withMycotic Diseases Branch, Centers for Disease Control and Prevention Email author 
  • , Tom M. ChillerAffiliated withMycotic Diseases Branch, Centers for Disease Control and Prevention

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Cryptococcal meningitis (CM), a fungal disease caused by Cryptococcus species, is one of the most common opportunistic infections among persons with HIV/AIDS. The highest burden of disease is in sub-Saharan Africa and Southeast Asia, where limited access to antiretroviral treatment and appropriate antifungal therapy contributes to high mortality rates. Increasing focus has been placed on earlier detection and prevention of disease. Primary prophylaxis and screening may provide a survival benefit and can be cost-effective in settings where CM prevalence is high. The development of a new point-of-care cryptococcal antigen assay has the potential to transform both disease prevention and diagnosis.


HIV Cryptococcal meningitis Cryptococcus Antiretroviral treatment Cryptococcal antigen assay AIDS HAART Prophylaxis Detection Prevention Point-of-care assay Developing countries Screening